January/February 2023

Now that the US medicines regulator has granted accelerated approval for the Alzheimer’s drug lecanemab, the way is clear for similar approvals in the UK and Europe.  We have been here before, of course, when the American Food and Drug Administration gave qualified approval two years ago to another monoclonal antibody drug called aducanumab, which…...

By Keith Oliver The start of the New Year is an ideal time to revisit or reconsider what has gone before and what might lie ahead. It seems quite unbelievable that 12 years ago, when I was diagnosed with Alzheimer’s disease, I could not find any books written by or with a person with dementia…....